Revolution Medicines has a big drug making headlines, and Royalty Pharma gets a bite of the action without doing anything at all.
Revolution Medicines (RVMD) is back in focus after third quarter earnings showed revenue of US$197.56 million and a net loss of US$407.46 million, driven largely by the recent RASONQUE launch. Investors have reacted quickly to the RASONQUE launch and earnings update, with Revolution Medicines’ share price up 8.24% over the past day even as the 30 day share price return is down 4.28% and the 90 day share price return is down 6.27%. At the same time, the year to date share price return of...
Revolution Medicines reported third quarter 2026 revenue of US$197.56 million, driven entirely by the early U.S. launch of RASONQUE for metastatic pancreatic cancer. The business continued to post substantial net losses and a higher loss per share over both the quarter and the first nine months of the year. The same product launch that generated US$197.6 million of net product revenue in roughly five weeks also treated more than 5,000 U.S. patients and secured preferred status in NCCN...
Revolution Medicines posts $198M Q3 revenue from RASONQUE’s launch, but the rich valuation limits upside. Click to read this most recent analysis of RVMD stock.
Motley Fool Press Release.
Stocks from many sectors flash buy signals, but avoid this area.
Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed RASONQUE consistently provided an overall survival benefit compared with chemotherapy across key subgroups, including patients with no identified tumor RAS mutationFindings presented as late-breaking abstract during Proffered Paper session REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commerc
Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer.
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
William Blair sets $226 price target for Revolution Medicines (RVMD) following Rasonque approval and major oncology expansion plans.
Innovation pays off.
This is the newest page. Registered accounts read further back.